NASDAQ:ACET Adicet Bio - ACET News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.15 +0.46 (+5.29%) (As of 01/31/2023 05:18 PM ET) Add Compare Share Share Today's Range$8.69▼$9.2750-Day Range$7.63▼$20.1952-Week Range$7.42▼$21.87Volume355,553 shsAverage Volume556,693 shsMarket Capitalization$392.08 millionP/E RatioN/ADividend YieldN/APrice Target$27.71 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get Adicet Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Email Address ACET Media Mentions By Week ACET Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACET News Sentiment▼0.440.72▲Average Medical News Sentiment ACET News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACET Articles This Week▼41▲ACET Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAdicet Bioforbes.com - January 26 at 7:18 AMAre Medical Stocks Lagging Adicet Bio (ACET) This Year?finance.yahoo.com - January 25 at 3:29 PMACET.C - | Stock Price & Latest News | Reutersreuters.com - January 25 at 10:13 AMShort Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 6.8%americanbankingnews.com - January 24 at 7:57 AMDown -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)finance.yahoo.com - December 30 at 1:09 PMShareholders in Adicet Bio (NASDAQ:ACET) have lost 49%, as stock drops 22% this past weekfinance.yahoo.com - December 20 at 9:49 AMAdicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornermsn.com - December 14 at 2:10 PMPeering Into Adicet Bio's Recent Short Interestmsn.com - December 13 at 6:08 PMAdicet Bio Shares Fall After Underwhelming Data From Non-Hodgkin's Lymphoma Studyfinance.yahoo.com - December 12 at 9:07 PMAdicet Bio plunges 38% after updating Phase 1 data for blood cancer therapyseekingalpha.com - December 12 at 3:57 PMAdicet Bio Plummets After Cancer Drug Trial Disappoints Investorsbloomberg.com - December 12 at 3:57 PMAdicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)finance.yahoo.com - December 10 at 4:21 PMWhat Makes Adicet Bio, Inc. (ACET) a Good Fit for 'Trend Investing'nasdaq.com - December 7 at 5:44 PMIs Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?finance.yahoo.com - December 7 at 5:44 PMAdicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)finance.yahoo.com - December 2 at 8:54 AMAdicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summitfinance.yahoo.com - November 30 at 5:14 PMWall Street Analysts Think Adicet Bio, Inc. (ACET) Could Surge 72%: Read This Before Placing a Betfinance.yahoo.com - November 29 at 1:12 PMAdicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officerfinance.yahoo.com - November 29 at 8:11 AMIs Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?msn.com - November 11 at 12:57 PMWall Street Analysts See a 39% Upside in Adicet Bio, Inc. (ACET): Can the Stock Really Move This High?msn.com - November 11 at 12:57 PMAdicet Bio Third Quarter 2022 Earnings: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)finance.yahoo.com - November 11 at 7:56 AMAdicet Bio, Inc. (ACET) Reports Q3 Loss, Misses Revenue Estimatesmsn.com - November 8 at 9:46 PMAdicet Reports Third Quarter 2022 Financial Results and Provides Business Updatesfinance.yahoo.com - November 8 at 4:30 PMAdicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meetingfinance.yahoo.com - November 7 at 11:49 AMBTIG Keeps Their Buy Rating on Adicet Bio (ACET)markets.businessinsider.com - November 4 at 6:01 AMAdicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)finance.yahoo.com - November 3 at 12:10 PMAdicet Bio to Present at the 2022 Jefferies London Healthcare Conferencefinance.yahoo.com - November 1 at 7:10 AMCalculating The Intrinsic Value Of Adicet Bio, Inc. (NASDAQ:ACET)finance.yahoo.com - October 23 at 12:30 PMA Look At The Intrinsic Value Of Adicet Bio, Inc. (NASDAQ:ACET)nasdaq.com - October 14 at 6:28 PMAdicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meetingfinance.yahoo.com - October 5 at 1:29 PMRedwood City biotech adds space exactly where it needed it: 'We just didn't have enough room'bizjournals.com - September 13 at 12:59 PMAdicet Bio, Inc. (NASDAQ:ACET) Receives Average Recommendation of "Moderate Buy" from Analystsamericanbankingnews.com - September 12 at 6:27 AMDespite shrinking by US$93m in the past week, Adicet Bio (NASDAQ:ACET) shareholders are still up 99% over 1 yearnasdaq.com - August 16 at 8:42 PMThe Consensus EPS Estimates For Adicet Bio, Inc. (NASDAQ:ACET) Just Fell Dramaticallyfinance.yahoo.com - August 16 at 10:41 AMAdicet Bio, (ACET) Investor Presentation - Slideshowseekingalpha.com - August 14 at 9:59 PMAdicet Bio Posts Wider Loss In Q2nasdaq.com - August 10 at 1:06 PMAdicet Bio, Inc. (ACET) Reports Q2 Loss, Misses Revenue Estimatesfinance.yahoo.com - August 10 at 1:06 PMAdicet Bio, Inc. (ACET) Is a Great Choice for "Trend" Investors, Here's Whyfinance.yahoo.com - July 18 at 11:54 AMAdicet Bio updates Phase 1 data for CAR-T candidate in blood cancerseekingalpha.com - June 6 at 11:47 AMAdicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meetingfinance.yahoo.com - June 6 at 11:47 AMAdicet Bio gains after updating early-stage data for CAR-T therapy in blood cancerseekingalpha.com - May 27 at 11:29 AMAdicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)finance.yahoo.com - May 26 at 8:20 PMAdicet Bio to Present at Upcoming Investor Conferencesfinance.yahoo.com - May 18 at 5:09 PMResults: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profitfinance.yahoo.com - May 15 at 9:42 AMAdicet Reports First Quarter 2022 Financial Results and Provides Business Updatesfinance.yahoo.com - May 13 at 2:06 AMFurther weakness as Adicet Bio (NASDAQ:ACET) drops 31% this week, taking one-year losses to 17%finance.yahoo.com - May 12 at 3:26 PMAdicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignanciesfinance.yahoo.com - May 5 at 8:53 AMAdicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meetingfinance.yahoo.com - April 27 at 10:50 AMAdicet Bio stock soars 13% on FDA fast track status for ADI-001 to treat blood cancerseekingalpha.com - April 19 at 9:04 AMAdicet Bio's Lead Candidate ADI-001 Gets FDA Fast Track Designation - Quick Factsnasdaq.com - April 19 at 9:04 AM Get Adicet Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:ACET) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.